182 related articles for article (PubMed ID: 38030811)
1. CASC4/GOLM2 drives high grade serous carcinoma anoikis resistance through the recycling of EGFR.
Bapat J; Yamamoto TM; Woodruff ER; Qamar L; Mikeska RG; Aird KM; Watson ZL; Brubaker LW; Bitler BG
Cancer Gene Ther; 2024 Feb; 31(2):300-310. PubMed ID: 38030811
[TBL] [Abstract][Full Text] [Related]
2. [Significance and expression of PAX8, PAX2, p53 and RAS in ovary and fallopian tubes to origin of ovarian high grade serous carcinoma].
Mao YN; Zeng LX; Li YH; Liu YZ; Wu JY; Li L; Wang Q
Zhonghua Fu Chan Ke Za Zhi; 2017 Oct; 52(10):687-696. PubMed ID: 29060967
[No Abstract] [Full Text] [Related]
3. CXCL10 alters the tumour immune microenvironment and disease progression in a syngeneic murine model of high-grade serous ovarian cancer.
K Au K; Peterson N; Truesdell P; Reid-Schachter G; Khalaj K; Ren R; Francis JA; Graham CH; Craig AW; Koti M
Gynecol Oncol; 2017 Jun; 145(3):436-445. PubMed ID: 28318643
[TBL] [Abstract][Full Text] [Related]
4. Norepinephrine induces anoikis resistance in high-grade serous ovarian cancer precursor cells.
Reavis HD; Gysler SM; McKenney GB; Knarr M; Lusk HJ; Rawat P; Rendulich HS; Mitchell MA; Berger DS; Moon JS; Ryu S; Mainigi M; Iwanicki MP; Hoon DS; Sanchez LM; Drapkin R
JCI Insight; 2024 Mar; 9(5):. PubMed ID: 38271085
[TBL] [Abstract][Full Text] [Related]
5. Targeting Fatty Acid Oxidation to Promote Anoikis and Inhibit Ovarian Cancer Progression.
Sawyer BT; Qamar L; Yamamoto TM; McMellen A; Watson ZL; Richer JK; Behbakht K; Schlaepfer IR; Bitler BG
Mol Cancer Res; 2020 Jul; 18(7):1088-1098. PubMed ID: 32198139
[TBL] [Abstract][Full Text] [Related]
6. Increased expression of neurotensin in high grade serous ovarian carcinoma with evidence of serous tubal intraepithelial carcinoma.
Norris EJ; Zhang Q; Jones WD; DeStephanis D; Sutker AP; Livasy CA; Ganapathi RN; Tait DL; Ganapathi MK
J Pathol; 2019 Jul; 248(3):352-362. PubMed ID: 30883751
[TBL] [Abstract][Full Text] [Related]
7. PAX2 function, regulation and targeting in fallopian tube-derived high-grade serous ovarian cancer.
Modi DA; Tagare RD; Karthikeyan S; Russo A; Dean M; Davis DA; Lantvit DD; Burdette JE
Oncogene; 2017 May; 36(21):3015-3024. PubMed ID: 27991925
[TBL] [Abstract][Full Text] [Related]
8.
Saini U; Suarez AA; Naidu S; Wallbillich JJ; Bixel K; Wanner RA; Bice J; Kladney RD; Lester J; Karlan BY; Goodfellow PJ; Cohn DE; Selvendiran K
Cancer Res; 2018 Apr; 78(7):1739-1750. PubMed ID: 29339537
[TBL] [Abstract][Full Text] [Related]
9. Long Non-Coding RNA HAND2-AS1 Acts as a Tumor Suppressor in High-Grade Serous Ovarian Carcinoma.
Gokulnath P; de Cristofaro T; Manipur I; Di Palma T; Soriano AA; Guarracino MR; Zannini M
Int J Mol Sci; 2020 Jun; 21(11):. PubMed ID: 32517089
[TBL] [Abstract][Full Text] [Related]
10. Targeting IDH1 as a Prosenescent Therapy in High-grade Serous Ovarian Cancer.
Dahl ES; Buj R; Leon KE; Newell JM; Imamura Y; Bitler BG; Snyder NW; Aird KM
Mol Cancer Res; 2019 Aug; 17(8):1710-1720. PubMed ID: 31110157
[TBL] [Abstract][Full Text] [Related]
11. A distinct pre-existing inflammatory tumour microenvironment is associated with chemotherapy resistance in high-grade serous epithelial ovarian cancer.
Koti M; Siu A; Clément I; Bidarimath M; Turashvili G; Edwards A; Rahimi K; Mes-Masson AM; Squire JA
Br J Cancer; 2015 Mar; 112(7):1215-22. PubMed ID: 25826225
[TBL] [Abstract][Full Text] [Related]
12. Single-cell RNA-sequencing analysis reveals divergent transcriptome events between platinum-sensitive and platinum-resistant high-grade serous ovarian carcinoma.
Wang Z; Yang L; Su X; Wu X; Su R
J Gene Med; 2023 Oct; 25(10):e3504. PubMed ID: 36994597
[TBL] [Abstract][Full Text] [Related]
13. Genomic catastrophe, the peritoneal cavity and ovarian cancer prevention.
Yoon JY; Chapel DB; Goebel E; Qian X; Mito JK; Horowitz NS; Miron A; Soong TR; Xian W; Crum CP
J Pathol; 2022 Jul; 257(3):255-261. PubMed ID: 35238033
[TBL] [Abstract][Full Text] [Related]
14. Defining the molecular evolution of extrauterine high grade serous carcinoma.
Beirne JP; McArt DG; Roddy A; McDermott C; Ferris J; Buckley NE; Coulter P; McCabe N; Eddie SL; Dunne PD; O'Reilly P; Gilmore A; Feeney L; Ewing DL; Drapkin RI; Salto-Tellez M; Kennedy RD; Harley IJG; McCluggage WG; Mullan PB
Gynecol Oncol; 2019 Nov; 155(2):305-317. PubMed ID: 31493898
[TBL] [Abstract][Full Text] [Related]
15. Loss of calponin h1 confers anoikis resistance and tumor progression in the development of high-grade serous carcinoma originating from the fallopian tube epithelium.
Wang KH; Chu SC; Chu TY
Oncotarget; 2017 Sep; 8(37):61133-61145. PubMed ID: 28977852
[TBL] [Abstract][Full Text] [Related]
16. Notch3 signaling promotes tumor cell adhesion and progression in a murine epithelial ovarian cancer model.
Price JC; Azizi E; Naiche LA; Parvani JG; Shukla P; Kim S; Slack-Davis JK; Pe'er D; Kitajewski JK
PLoS One; 2020; 15(6):e0233962. PubMed ID: 32525899
[TBL] [Abstract][Full Text] [Related]
17. Peritoneal dissemination of high-grade serous ovarian cancer: pivotal roles of chromosomal instability and epigenetic dynamics.
Konishi I; Abiko K; Hayashi T; Yamanoi K; Murakami R; Yamaguchi K; Hamanishi J; Baba T; Matsumura N; Mandai M;
J Gynecol Oncol; 2022 Sep; 33(5):e83. PubMed ID: 36032027
[TBL] [Abstract][Full Text] [Related]
18. PAX8 activates a p53-p21-dependent pro-proliferative effect in high grade serous ovarian carcinoma.
Ghannam-Shahbari D; Jacob E; Kakun RR; Wasserman T; Korsensky L; Sternfeld O; Kagan J; Bublik DR; Aviel-Ronen S; Levanon K; Sabo E; Larisch S; Oren M; Hershkovitz D; Perets R
Oncogene; 2018 Apr; 37(17):2213-2224. PubMed ID: 29379162
[TBL] [Abstract][Full Text] [Related]
19. Loss of PRP4K drives anoikis resistance in part by dysregulation of epidermal growth factor receptor endosomal trafficking.
Corkery DP; Clarke LE; Gebremeskel S; Salsman J; Pinder J; Le Page C; Meunier L; Xu Z; Mes-Masson AM; Berman JN; Johnston B; Dellaire G
Oncogene; 2018 Jan; 37(2):174-184. PubMed ID: 28892043
[TBL] [Abstract][Full Text] [Related]
20. ALDH1A1-related stemness in high-grade serous ovarian cancer is a negative prognostic indicator but potentially targetable by EGFR/mTOR-PI3K/aurora kinase inhibitors.
Kaipio K; Chen P; Roering P; Huhtinen K; Mikkonen P; Östling P; Lehtinen L; Mansuri N; Korpela T; Potdar S; Hynninen J; Auranen A; Grénman S; Wennerberg K; Hautaniemi S; Carpén O
J Pathol; 2020 Feb; 250(2):159-169. PubMed ID: 31595974
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
